Biocon gets European Commission nod for breast cancer biosimilar Pebrilzo

In this photo illustration a Biocon Limited logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Biopharmaceutical firm Biocon Ltd has received marketing authorisation from the European Commission (EC) for Pebrilzo, its pertuzumab biosimilar, to treat HER2-positive breast cancer across multiple disease stages in the European Union.

Biocon’s pertuzumab is the first biosimilar to receive EC marketing authorisation under the European Medicines Agency’s (EMA) new tailored clinical approach, the company said in a regulatory filing on Wednesday.

The approval follows a positive CHMP opinion on September 17, 2026, and a recent US Food and Drug Administration (USFDA) approval for the biosimilar, it added.

“The European Commission’s approval of Pebrilzo, our pertuzumab biosimilar, the first under its new tailored clinical pathway, marks a significant regulatory milestone for Biocon,” Biocon CEO and Managing Director Shreehas Tambe said.

“With this approval, pertuzumab becomes our fifth oncology biosimilar approved in both Europe and the United States, strengthening our global oncology portfolio and reinforcing our commitment to expanding access to high-quality, affordable biologic therapies for patients with HER2-positive breast cancer,” he added.

Approved as a 420 mg concentrate for solution for infusion, the biosimilar is indicated for use in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer at high risk of recurrence, as well as in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence, the filing said.

In addition, it is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease, the company added.

-PTI

RELATED ARTICLES

10 mins ago | Crimean Bridge

Ukraine cripples Crimean road bridge in blow to Putin before meeting with Xi and Trump

Ukrainian drones and missiles destroyed the central road section of the bridge linking Russia and Crimea on Tuesday, inflicting a military and symbolic blow on President Vladimir Putin two days before he is due to meet the leaders of China and the US...

16 mins ago | Iranian attacks

Bahrain, Kuwait report Iranian attacks; US strikes Iranian missile site on Qeshm Island

Kuwait and Bahrain reported fresh Iranian attacks on Wednesday, amid renewed escalation in hostilities between the USA and Iran starting last week. Kuwait's Army posted on social media around midnight that their air defences were responding to hostil...

21 mins ago | 16-day yatra

Nitin Nabin to flag off 16-day yatra in Punjab under BJP’s campaign to mark Guru Ravidas’ birth anniversary

BJP national president Nitin Nabin will on Wednesday flag off a 16-day 'Samrasta Sankalp Yatra' from Jalandhar in Punjab as part of the party's year-long celebrations marking the 650th birth anniversary of Guru Ravidas. Nabin will offer prayers at S...